- Home
- EMAT vs TNGX Comparison
EMAT vs TNGX Comparison
Compare EMAT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMAT | TNGX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EMAT | TNGX |
|---|---|---|
| Price | $9.20 | $23.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $30.00 | $21.78 |
| AVG Volume (30 Days) | 102.4K | ★ 2.9M |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,122.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $5.50 | $1.04 |
| 52 Week High | $17.50 | $28.41 |
Technical Indicators
Market Signals| Indicator | EMAT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 52.25 |
| Support Level | $6.61 | $6.83 |
| Resistance Level | $15.00 | $28.41 |
| Average True Range (ATR) | 0.73 | 1.83 |
| MACD | 0.13 | -0.70 |
| Stochastic Oscillator | 63.95 | 31.70 |
Price Performance
Historical ComparisonAbout EMAT Evolution Metals & Technologies Corp. Common Stock
Evolution Metals & Technologies Corp is a critical materials and technology company. The company is focused on developing a secure, dependable, and self-sustaining U.S.-aligned supply chain for critical minerals and materials (CMM), and rare earth elements (REEs). The company is also engaged in recycling end-of-life materials through urban mining to help strengthen domestic resource independence and long-term supply stability.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.